Establishing the optimal duration of DAPT following PCI in high‐risk TWILIGHT‐like patients with acute coronary syndrome

• Published in: Catheterization and cardiovascular interventions 2022-01, Vol.99 (1), p.98-113
• Main Authors: Wang, Hao‐Yu, Mo, Ran, Guan, Chang‐Dong, Wang, Yang, Zhao, Yan‐Yan, Xie, Li‐Hua, Zhang, Rui, Cai, Zhong‐Xing, Xu, Bo, Dou, Ke‐Fei
• Format: Article
• Language: English
• Subjects: ACS/NSTEMI; Acute Coronary Syndrome - drug therapy; Acute Coronary Syndrome - therapy; Acute coronary syndromes; Antiplatelet therapy; Bleeding; Cerebral infarction; drug eluting (DES); Drug Therapy, Combination; Hemorrhage; Humans; Implants; Ischemia; Myocardial infarction; Patients; percutaneous coronary intervention (PCI); Percutaneous Coronary Intervention - adverse effects; Platelet Aggregation Inhibitors - adverse effects; Prospective Studies; stent; Thrombosis; Treatment Outcome
• ISSN: 1522-1946; 1522-726X
• DOI: 10.1002/ccd.29741

Objectives To determine the association of extended‐term (>12‐month) versus short‐term dual antiplatelet therapy (DAPT) with ischemic and hemorrhagic events in high‐risk “TWILIGHT‐like” patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) in clinical practice. Background Recent emphasis on shorter DAPT regimen after PCI irrespective of indication for PCI may fail to account for the substantial residual risk of recurrent atherothrombotic events in ACS patients. Methods All consecutive patients fulfilling the “TWILIGHT‐like” criteria undergoing PCI were identified from the prospective Fuwai PCI Registry. High‐risk patients (n = 8,358) were defined by at least one clinical and one angiographic feature based on TWILIGHT trial selection criteria. The primary ischemic endpoint was major adverse cardiac and cerebrovascular events at 30 months, composed of all‐cause mortality, myocardial infarction, or stroke while BARC type 2, 3, or 5 bleeding was key secondary outcome. Results Of 4,875 high‐risk ACS patients who remained event‐free at 12 months after PCI, DAPT>12‐month compared with shorter DAPT reduced the primary ischemic endpoint by 63% (1.5 vs. 3.8%; HRadj: 0.374, 95% CI: 0.256–0.548; HRmatched: 0.361, 95% CI: 0.221–0.590). The HR for cardiovascular death was 0.049 (0.007–0.362) and that for MI 0.45 (0.153–1.320) and definite/probable stent thrombosis 0.296 (0.080–1.095) in propensity‐matched analyses. Rates of BARC type 2, 3, or 5 bleeding (0.9 vs. 1.3%; HRadj: 0.668 [0.379–1.178]; HRmatched: 0.721 [0.369–1.410]) did not differ significantly between two groups. Conclusions Among high‐risk ACS patients undergoing PCI, long‐term DAPT, compared with shorter DAPT, reduced ischemic events without a concomitant increase in clinically meaning bleeding events, suggesting that prolonged DAPT can be considered in ACS patients who present with a particularly higher risk for thrombotic complications without excessive risk of bleeding.